Avalo Therapeutics, Inc. rose 18.9% on Wednesday, November 11, 2026, on 1,839,400 shares. The headline around the move:
Avalo Therapeutics, Inc. (AVTX:NASDAQ) closed at $7.76 on November 13, 2026, up 0.78% on the day. The stock trades 68.0% below its 52-week high of $24.27 and 18.8% above its 52-week low of $6.53. Over the past year, it lost 54.0%. Avalo Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, AVTX closed higher on 115 days (46%). Its best day was May 6, 2026 (+34.13%) and its worst was October 22, 2026 (-39.23%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 1 time.
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, AVTX-006, AVTX 800 programs (AVTX-801, AVTX-802, and AVTX-803).
Find more stocks like AVTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.